Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2026)
Artiva Biotherapeutics' (ARTV) quarterly Cash from Financing Activities came in at -$112000.0 in Q1 2026, down 146.86% year-on-year from $239000.0 in Q1 2025, and up 7.44% on a QoQ basis from -$121000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has 4 years of Cash from Financing Activities data on file, last reported at -$112000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 146.86% year-over-year to -$112000.0 in Q1 2026; TTM through Mar 2026 was -$342000.0, a 100.21% decrease from a year earlier, with the FY2025 full-year figure at $9000.0, down 99.99% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$112000.0, up from -$121000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for ARTV reached as high as $163.9 million in Q3 2024 and fell as low as -$121000.0 in Q4 2025.
- Historically, Cash from Financing Activities has averaged $20.9 million across 4 years, with a median of -$30000.0 in 2024.
- Across the five-year window, Cash from Financing Activities surged 599.38% in 2024 and slumped 303.33% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $962000.0 in 2023, then sank by 103.12% to -$30000.0 in 2024, then slumped by 303.33% to -$121000.0 in 2025, then advanced by 7.44% to -$112000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$112000.0 in Q1 2026, -$121000.0 in Q4 2025, and -$37000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Artiva Biotherapeutics | 249.99 Mn | 249.99 Mn | - | -112,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -112,000.00 |
| Mar 31, 2026 | -112,000.00 |
| Dec 31, 2025 | -121,000.00 |
| Dec 31, 2025 | -121,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Sep 30, 2025 | -37,000.00 |
| Jun 30, 2025 | -72,000.00 |
| Jun 30, 2025 | -72,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | 163.87 Mn |
| Sep 30, 2024 | 163.87 Mn |
| Dec 31, 2023 | 962,000.00 |
| Dec 31, 2023 | 962,000.00 |
| Sep 30, 2023 | 23.43 Mn |
| Sep 30, 2023 | 23.43 Mn |